Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential ThrombocythemiaJohn Mascarenhas, Robert S. Hoffman, Josef T. Prchal et al.|Blood|2016Cited by 28
Safety and Efficacy of Combined Ruxolitinib and Decitabine in Patients with Blast-Phase MPN and Post-MPN AML: Results of a Phase I Study (Myeloproliferative Disorders Research Consortium 109 trial)Raajit K. Rampal, Ronald Hoffman, John Mascarenhas et al.|Blood|2016Cited by 14
The change in Ig regulation from children to adults disconnects the correlation with the 3’RR hs1.2 polymorphismEliseo Serone, Domenico Frezza, Renato Massoud et al.|BMC Immunology|2014Cited by 9
Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III TrialRuben A. Mesa, John Mascarenhas, Robert S. Hoffman et al.|Blood|2016Cited by 5
New insight of human-IgH 3′regulatory regions in immunoglobulins switchRossella Cianci, Domenico Frezza, Giorgio Mancino et al.|Gene|2023Cited by 3